Welding World Awards 2018 raises over £10,000
Kidney Cancer UK were delighted to be the beneficiary of the The Welding World Awards 2018 Gala dinner on Wednesday 11th April. Alice... Read More
Preliminary results for avelumab + axitinib..
…. as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial... Read More
Nivolumab approved for monthly use in USA
US regulators have approved a label update to Bristol-Myers Squibb’s Opdivo, waving through a new dosing option for the immunotherapy of every... Read More
NICE recommends tivozanib as first-line treatment for advanced renal cell carcinoma
EUSA Pharma has announced that the National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending... Read More
Cabozantinib Yields Similar QoL Outcomes to Everolimus in RCC
Patients with advanced renal cell carcinoma had an improved time to deterioration (TTD) and similar quality of life (QoL) after treatment with cabozantinib compared... Read More
Cabozantinib Bests Everolimus in RCC with Bone Metastases
Cabozantinib (Cabometyx) was more effective than everolimus (Afinitor) in patients with advanced renal cell carcinoma and bone metastases, according to a subgroup... Read More
SABR for Renal Cell Carcinoma Offers Excellent Outcomes
Stereotactic ablative radiotherapy (SABR) for patients with primary renal cell carcinoma (RCC) is well tolerated and is associated with excellent local oncologic control,... Read More
3D Printed Prostates Could Improve Preoperative Planning and Developed for RCC
Researchers have developed a new technique for 3D printing (printed) patient-specific prostate glands using polymers that accurately model a prostate’s dimensions and physical... Read More
MRI technology bypasses need for biopsy
The most common type of tumor found in the kidney is generally quite small (less than 1.5 in). These tumors are usually... Read More
Serious fatigue with Sorafenib & Sunitinib by RCC patients
Sorafenib, and particularly sunitinib, worsened the severity of fatigue among patients with renal cell carcinoma (RCC) compared with placebo, according to a... Read More
Promise in US Trial for Advanced Metastatic RCC
New data from a Phase 1 clinical trial shows that ARMO BioSciences‘ immunotherapy AM0010 (pegilodecakin), alone or in combination with immune checkpoint inhibitors, shows high and durable clinical responses in patients with advanced renal cell carcinoma (RCC).
The Evolving Management of Advanced Renal Cell Carcinoma
A review from the American website Urototady.com of Dr. Rana R. McKay State-of-the-Art lecture providing a comprehensive presentation of the evolving management... Read More
Vaccine for Renal Cancer Passes Early Test
A vaccine against metastatic renal cell carcinoma appears to have some activity in patients who receive engineered autologous dendritic cell infusions, researchers reported here at the International Kidney Cancer Symposium.
Nivolumab Improves 3-year Overall Survival in Previously Treated Renal Cell Carcinoma
Updated results from a phase 3 study demonstrated that patients with advanced renal cell carcinoma (RCC) treated with nivolumab had significantly superior rates of 3-year overall survival (OS) compared with everolimus,
kidney cancer drug test stopped after early success
(Reuters) – Bristol-Myers Squibb Co said on Thursday the success of its combination therapy to improve overall survival in kidney cancer patients... Read More
Tivozanib Approved in Europe for Kidney Cancer
The European Commission (EC) has approved tivozanib (Fotivda) for the treatment of patients with advanced renal cell carcinoma (RCC), according to AVEO,... Read More
MRI test could predict kidney cancer patients who may benefit from anti-vascular therapy
A magnetic resonance imaging (MRI) test that measures the volume of blood in tumours could help select which patients will benefit from... Read More
Mixed results for Opdivo/ Yervoy combo
A combination of Bristol-Myers Squibb’s Opdivo (nivolumab)and Yervoy (ipilimumab) has failed to significantly improve progression-free survival (PFS) compared to Pfizer’s Sutent in patients... Read More
Shorter Telomere Length Predicts Cancer in Patients With VHL
Shorter blood telomere length is a biomarker for tumor risk in patients with Von Hippel-Lindau (VHL) syndrome, according to an article published... Read More
microRNAs and the Future of Renal Cell Carcinoma Treatment
Researchers in America are zeroing in on microRNAs (miRNAs) circulating in the bloodstream as biomarkers for the detection and diagnosis of renal... Read More
Tests in USA on epacadostat and Keytruda combination
Incyte Corp. and Merck will work together in the USA to study the combination of epacadostat and Keytruda in people fighting several... Read More
Britain lagging behind Europe in diagnosing and treating cancer, report finds
The UK is trailing behind other European countries when it comes to diagnosing and treating cancer, a new report says. The study,... Read More
New treatment option: Cabozantinib is now available for use in the NHS for advanced kidney cancer patients
Kidney Cancer UK is delighted that National Institute for Health and Care Excellence (NICE) has recommended the drug cabozantinib (Cabometyx) be made... Read More
Combo immunotherapy may herald new standard of care for kidney cancer
Kidney Cancer UK has previously described the potential of combining different immunotherapy drugs for the treatment of advanced kidney cancer. Following the... Read More